TLSI
TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.00
+0.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 45.1M | 45.2M | 29.4M | 18.5M | 12.4M |
| Cost of Revenue | 6.4M | 7.0M | 4.1M | 2.6M | 2.3M |
| Gross Profit | 38.7M | 38.2M | 25.3M | 15.9M | 10.1M |
| Operating Expenses | |||||
| R&D Expense | 14.1M | 15.0M | 17.7M | 29.8M | 21.4M |
| SG&A Expense | 55.1M | 50.2M | 43.8M | 40.5M | 25.2M |
| General & Admin Expense | 21.4M | 21.5M | 18.0M | 23.5M | 12.5M |
| Selling & Marketing Expense | 33.6M | 28.7M | 25.8M | 17.0M | 12.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 69.2M | 65.1M | 61.5M | 70.4M | 46.6M |
| Cost and Expenses | 75.6M | 72.1M | 65.6M | 73.0M | 48.8M |
| Operating Income (EBIT) | (30.5M) | (26.9M) | (36.2M) | (54.5M) | (36.4M) |
| Non-Operating | |||||
| Interest Income | 968.0K | 555.0K | 404.0K | 431.0K | 180.0K |
| Interest Expense | 5.8M | 5.5M | 3.1M | 16.0K | 1.0K |
| Net Interest Income | (4.9M) | (5.0M) | (2.7M) | 415.0K | 179.0K |
| Other Non-Op Income/Expense | 2.3M | (12.3M) | 6.1M | (4.9M) | (10.7M) |
| Non-Operating Income (excl Interest) | (8.1M) | 6.7M | (3.0M) | 4.9M | 10.7M |
| EBT (Pre-Tax Income) | (28.2M) | (39.2M) | (30.0M) | (59.4M) | (47.2M) |
| Income Tax Expense | 13.0K | 7.0K | 6.0K | 9.0K | 9.0K |
| Bottom Line | |||||
| Net Income | (28.2M) | (39.2M) | (33.2M) | (59.4M) | (47.2M) |
| Earnings from Cont. Ops | (28.2M) | (39.2M) | (30.0M) | (59.4M) | (47.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (58.7M) | (69.7M) | (33.2M) | (63.6M) | (50.0M) |
| Per Share | |||||
| Basic EPS | ($1.30) | ($1.84) | ($1.25) | ($2.23) | ($1.59) |
| Diluted EPS | ($1.30) | ($1.84) | ($1.25) | ($2.23) | ($1.59) |
| Revenue Per Share | $0.77 | $1.19 | $1.11 | $0.70 | $0.42 |
| Shares | |||||
| Basic Shares Outstanding | 58.3M | 37.9M | 26.5M | 26.5M | 29.6M |
| Diluted Shares Outstanding | 58.3M | 37.9M | 26.5M | 26.5M | 29.6M |
| Profitability Metrics | |||||
| EBITDA | (21.7M) | (33.0M) | (32.4M) | (58.7M) | (46.8M) |
| D&A | 695.0K | 626.0K | 744.0K | 684.0K | 414.0K |
| EBIT | (22.4M) | (33.7M) | (33.1M) | (59.3M) | (47.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026